Stock ALT ALTIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Altimmune, Inc.

Equities

ALT

US02155H2004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
6.455 USD -4.09% Intraday chart for Altimmune, Inc. -14.05% -42.62%
Jun. 05 Altimmune, Inc. Presents Data at EASL International Liver Congress?? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis CI
May. 23 Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
NE
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
PR
Altimmune Presents Data at EASL International Liver Congress 2024
AQ
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders
PR
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders
PR
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
PR
Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
AQ
Altimmune, Inc. Presents Data at EASL International Liver Congress?? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
CI
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT
PR
Altimmune : NAFLDsym Poster (Abstract #2881)
PU
Altimmune : EASL Pemvidutide Lipidomics MASH Poster (Abstract #2985)
PU
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
PR
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
PR
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
PR
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress 2024
AQ
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
PR
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
PR
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
AQ
Altimmune to Participate at Two Upcoming Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALT Stock
  4. News Altimmune, Inc.